Citation

Brunette MF, Oslin DW, Dixon LB, Adler DA, Berlant J, Erlich M, First MB, Goldman B, Levine B, Siris S, Winston H. Psychiatr. Serv. 2019; ePub(ePub): ePub.

Affiliation

Group for the Advancement of Psychiatry, Dallas (all authors); Department of Psychiatry, Geisel School of Medicine at Dartmouth, Hanover, New Hampshire (Brunette); Department of Psychiatry, Perelman School of Medicine, University of Pennsylvania and Philadelphia Veterans Administration Medical Center, Philadelphia (Oslin); Department of Psychiatry, Vagelos College of Physicians and Surgeons, Columbia University Irving Medical Center and New York State Psychiatric Institute, New York (Dixon, Erlich, First); Department of Psychiatry, Tufts Medical Center, Boston (Adler); Optum Idaho, Boise (Berlant); Department of Psychiatry, Donald and Barbara Zucker School of Medicine at Hofstra/Northwell, New York (Siris); Department of Psychiatry, University of Colorado School of Medicine, Aurora (Winston).

Copyright

(Copyright © 2019, American Psychiatric Association)

DOI

10.1176/appi.ps.201800582

PMID

31500545

Abstract

The number of people with opioid use disorder and the number of overdose deaths in the United States have increased dramatically over the past 20 years. U.S. Congress passed the SUPPORT for Patients and Communities Act, which was signed into law in 2018, authorizing almost $8 billion to address the crisis. As experts in the treatment of central nervous systems disorders, psychiatrists can play a leading role in expanding treatment for people with opioid use disorder and in advocating for policy changes to support community treatment for this group.

Language: en

Keywords

Administration and management; Alcohol and drug abuse; Buprenorphine; Opioid; Psychiatry